Home / Pharma News

Pharma News

Cipla and S&D Pharma make generics deal for Czech Republic and Slovakia

India-based generics maker Cipla has partnered with S&D Pharma to launch affordable, high quality generics in the Czech Republic and Slovakia.

Patients at risk from UK drug shortages

Ongoing drug shortages in the UK have led to 80% of general practitioners (GPs) surveyed reporting that their workloads have increased in the last year. A third of doctors say their patients have been harmed or been negatively affected if a second choice has had to be prescribed.

Investor principles on biosimilars gained support

Amgen and Novartis (parent company of Sandoz, a leader in the biosimilars field) have both come out in support of a set of principles on biosimilars laid down by a coalition of 19 institutional investors.

Branded drugmaker could be sued for generic’s side effects

The Alabama Supreme Court has ruled, for the second time, that Pfizer could be sued for damages allegedly caused by its heartburn drug Reglan (metoclopramide), even if the plaintiff had only taken a generic version of the drug. The ruling follows a rehearing requested by Pfizer, which failed to overturn the original ruling.

Generics shortages continue to rise in the UK

There is growing anxiety around the supply of generic medicines in the UK, according to a statement released by the country’s All-Party Pharmacy Group (APPG). The problem is worse than it was two years ago [1], say the cross-bench Members of Parliament who make up the group, and it is not being addressed by the Department of Health’s (DoH) supply chain forum which was set up to address this very issue.

Generics deals for Mylan, Pfizer and Sun Pharma

Not to be beaten by biosimilars manufacturers, generics makers are also jumping on the ‘deals’ bandwagon, with a plethora of collaborations announced in the past weeks.

Endo to buy generics maker DAVA

Specialty pharmaceuticals maker Endo Health Solutions (Endo) announced on 24 June 2014 that it had reached a definitive agreement to acquire generics maker DAVA Pharmaceuticals for US$575 million in cash, with another US$25 million up for grabs depending on the achievement of certain sales milestones.

Abbott to buy Russian generics firm

US-based pharma company Abbott Laboratories (Abbott) announced on 23 June 2014 that it had signed a definitive agreement to acquire Russian generics maker Veropharm.

Pfenex looking for funding for its biosimilars pipeline

US biotechnology firm Pfenex is looking to raise more than US$45 million to further its biosimilars pipeline.

Views on biosimilars at Amgen and Actavis

Biotech giant Amgen and US generics maker Actavis entered into a collaboration for the development and commercialization of several cancer antibody biosimilars back in December 2011 [1]. Now the two companies have spoken to GaBI about their views on biosimilars and their biosimilar plans [2].